<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000393537"><TermName>CC49-streptavidin</TermName><TermPronunciation>(… strep-TA-vih-din)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It is made by combining the monoclonal antibody CC49 with a chemical called streptavidin. It can find tumor cells that have the protein TAG-72 on their surface, including colon, prostate, breast, and ovary cancer cells. After CC49-streptavidin binds to cancer cells, a radioactive compound called yttrium Y 90 DOTA-biotin will find those cells and kill them.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000730919" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;CC49-streptavidin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000730918" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;CC49-estreptavidina&quot;" language="es" id="_4"/><SpanishTermName>CC49-estreptavidina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Se produce combinando el anticuerpo monoclonal CC49 con un producto químico llamado estreptavidina. El preparado puede encontrar las células tumorales que tienen la proteína GCT-72 en su superficie, inclusive las células cancerosas del colon, la próstata, la mama y el ovario. Después de que la CC49-estreptavidina se une a las células cancerosas, un compuesto radiactivo llamado itrio Y90 DOTA-biotina encuentra esas células y las destruye.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-11-22</DateFirstPublished></GlossaryTerm>
